449 related articles for article (PubMed ID: 26173796)
21. Real-world experiences: Efficacy and tolerability of pirfenidone in clinical practice.
Fang C; Huang H; Guo J; Ferianc M; Xu Z
PLoS One; 2020; 15(1):e0228390. PubMed ID: 31999801
[TBL] [Abstract][Full Text] [Related]
22. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.
Lederer DJ; Bradford WZ; Fagan EA; Glaspole I; Glassberg MK; Glasscock KF; Kardatzke D; King TE; Lancaster LH; Nathan SD; Pereira CA; Sahn SA; Swigris JJ; Noble PW
Chest; 2015 Jul; 148(1):196-201. PubMed ID: 25856121
[TBL] [Abstract][Full Text] [Related]
23. Real world experience of response to pirfenidone in patients with idiopathic pulmonary fibrosis: a two centre retrospective study.
Eaden JA; Barber CM; Renshaw SA; Chaudhuri N; Bianchi SM
Sarcoidosis Vasc Diffuse Lung Dis; 2020; 37(2):218-224. PubMed ID: 33093786
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and Safety of Pirfenidone in Advanced Idiopathic Pulmonary Fibrosis.
Yoon HY; Kim DS; Song JW
Respiration; 2019; 97(3):242-251. PubMed ID: 30332670
[TBL] [Abstract][Full Text] [Related]
25. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
[TBL] [Abstract][Full Text] [Related]
26. A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: the PolExPIR study.
Majewski S; Białas AJ; Buchczyk M; Gomółka P; Górska K; Jagielska-Len H; Jarzemska A; Jassem E; Jastrzębski D; Kania A; Koprowski M; Krenke R; Kuś J; Lewandowska K; Martusewicz-Boros MM; Roszkowski-Śliż K; Siemińska A; Sładek K; Sobiecka M; Szewczyk K; Tomczak M; Tomkowski W; Wiatr E; Ziora D; Żołnowska B; Piotrowski WJ
BMC Pulm Med; 2020 May; 20(1):122. PubMed ID: 32366291
[TBL] [Abstract][Full Text] [Related]
27. Pirfenidone in idiopathic pulmonary fibrosis: real-life experience from a German tertiary referral center for interstitial lung diseases.
Oltmanns U; Kahn N; Palmowski K; Träger A; Wenz H; Heussel CP; Schnabel PA; Puderbach M; Wiebel M; Ehlers-Tenenbaum S; Warth A; Herth FJ; Kreuter M
Respiration; 2014; 88(3):199-207. PubMed ID: 25115833
[TBL] [Abstract][Full Text] [Related]
28. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
[TBL] [Abstract][Full Text] [Related]
29. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Costabel U; Albera C; Lancaster LH; Lin CY; Hormel P; Hulter HN; Noble PW
Respiration; 2017; 94(5):408-415. PubMed ID: 28898890
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study.
Sakamoto S; Muramatsu Y; Satoh K; Ishida F; Kikuchi N; Sano G; Sugino K; Isobe K; Takai Y; Homma S
Respirology; 2015 Apr; 20(3):445-52. PubMed ID: 25639750
[TBL] [Abstract][Full Text] [Related]
31. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
Costabel U; Albera C; Bradford WZ; Hormel P; King TE; Noble PW; Sahn SA; Valeyre D; du Bois RM
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Oct; 31(3):198-205. PubMed ID: 25363219
[TBL] [Abstract][Full Text] [Related]
32. Serum surfactant protein D predicts the outcome of patients with idiopathic pulmonary fibrosis treated with pirfenidone.
Ikeda K; Shiratori M; Chiba H; Nishikiori H; Yokoo K; Saito A; Hasegawa Y; Kuronuma K; Otsuka M; Yamada G; Takahashi H
Respir Med; 2017 Oct; 131():184-191. PubMed ID: 28947028
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of Pirfenidone in the Context of Multiple Disease Progression Events in Patients With Idiopathic Pulmonary Fibrosis.
Nathan SD; Costabel U; Glaspole I; Glassberg MK; Lancaster LH; Lederer DJ; Pereira CA; Trzaskoma B; Morgenthien EA; Limb SL; Wells AU
Chest; 2019 Apr; 155(4):712-719. PubMed ID: 30472023
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis.
Sakamoto S; Itoh T; Muramatsu Y; Satoh K; Ishida F; Sugino K; Isobe K; Homma S
Intern Med; 2013; 52(22):2495-501. PubMed ID: 24240787
[TBL] [Abstract][Full Text] [Related]
35. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King TE; Bradford WZ; Castro-Bernardini S; Fagan EA; Glaspole I; Glassberg MK; Gorina E; Hopkins PM; Kardatzke D; Lancaster L; Lederer DJ; Nathan SD; Pereira CA; Sahn SA; Sussman R; Swigris JJ; Noble PW;
N Engl J Med; 2014 May; 370(22):2083-92. PubMed ID: 24836312
[TBL] [Abstract][Full Text] [Related]
36. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Ley B; Swigris J; Day BM; Stauffer JL; Raimundo K; Chou W; Collard HR
Am J Respir Crit Care Med; 2017 Sep; 196(6):756-761. PubMed ID: 28471697
[TBL] [Abstract][Full Text] [Related]
37. Real world experiences: pirfenidone is well tolerated in patients with idiopathic pulmonary fibrosis.
Chaudhuri N; Duck A; Frank R; Holme J; Leonard C
Respir Med; 2014 Jan; 108(1):224-6. PubMed ID: 24269005
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study.
Song MJ; Lee SH; Jung JY; Kang YA; Park MS; Kim YS; Chang J; Kim SY
BMC Pulm Med; 2021 May; 21(1):145. PubMed ID: 33941141
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
[TBL] [Abstract][Full Text] [Related]
40. Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study.
Suraj KP; Kumar NK; Jyothi E; Narayan KV; Biju G
J Assoc Physicians India; 2016 May; 64(5):36-41. PubMed ID: 27735147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
